PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
26 déc. 2023 18h00 HE
|
PainReform Ltd
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Third Quarter of 2023
15 nov. 2023 16h05 HE
|
PainReform Ltd
TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
11 sept. 2023 08h30 HE
|
PainReform Ltd
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd....
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
07 sept. 2023 10h00 HE
|
PainReform Ltd
TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
05 sept. 2023 08h30 HE
|
PainReform Ltd
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Second Quarter of 2023
10 août 2023 16h05 HE
|
PainReform Ltd
TEL AVIV, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
19 juil. 2023 09h00 HE
|
PainReform Ltd
TEL AVIV, Israel, July 19, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
14 juil. 2023 14h35 HE
|
PainReform Ltd
TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
12 juil. 2023 09h05 HE
|
PainReform Ltd
TEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
15 juin 2023 08h30 HE
|
PainReform Ltd
TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...